BlaeseMR, CulverKW, MillerDA, et al.T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science, 1995; 20:475–480.
2.
BennettJ, WellmanJ, MarshallKA, et al.Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on Phase 1 trial. Lancet, 2016; 388:661–672.
3.
MendellJR, Al-ZaidyS, ShellR, et al.Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.
KoenigM, HoffmanEP, BertelsonAP, et al.Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 1987; 50:509–517.
7.
GrozdanovicZ, BaumgartenHG. Nitric oxide synthase in skeletal muscle fibers: a signaling component of the dystrophin–glycoprotein complex. Histol Histopathol, 1999; 14:243–256.
8.
PatelA, ZhaoJ, YueY, et al.Dystrophin R16/17-syntrophin PDZ fusion protein restores sarcolemmal nNOSμ. Skelet Muscle, 2018; 8:36.
9.
MendellJR, MoxleyRT, GriggsRC, et al.Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med, 1989; 320:1592–1597.
10.
BrookeMH, FenichelGM, GriggsRC, et al.Clinical investigation in Duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve, 1983; 6:91–103.
11.
KarpatiG, AjdukovicD, ArnoldD, et al.Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol, 1993; 34:8–17.
12.
HuardJ, BouchardJP, RoyR, et al.Human myoblast transplantation: preliminary results of 4 cases. Muscle Nerve, 1992; 15:550–560.
13.
TremblayJP, MalouinF, RoyR, et al.Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant, 1993; 2:99–112.
14.
MendellJR, KisselJT, AmatoAA, et al.Randomized, double-blind, one year trial of myoblast transfer in Duchenne muscular dystrophy. N Engl J Med, 1995; 333:832–838.
15.
FisherKJ, ChoiH, BurdaJ, et al.Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology, 1996; 217:11–22.
16.
DudleyRW, LuY, GilbertR, et al.Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Hum Gene Ther, 2004; 15:145–156.
17.
Hartigan-O'ConnorD, AmalfitanoA, ChamberlainJS. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J Virol, 1999; 73:7835–7841.
18.
FlotteTR, AionoSA, ConradCet al.Stable in vivo expression of the cystic fibrosis transmembrane regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A, 1993; 90:10610–10617.
19.
HerzogRW, HagstromJN, KungS-H, et al.Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A, 1997; 94:5804–5809.
20.
MendellJR, Rodino-KlapacLR, Rosales-QuinteroX, et al.LGMD2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol, 2009; 66:290–297.
21.
MendellJR, Rodino-KlapacLR, Rosales-QuinteroX, et al.Sustained alpha-sarcoglycan gene expression following gene transfer in LGMD2D. Ann Neurol, 2010; 68:629–638.
22.
MendellJR, CampbellK, Rodino-KlapacL, et al.Dystrophin immunity revealed by gene therapy in Duchenne muscular dystrophy. N Engl J Med, 2010; 363:1429–1437.
23.
MendellJR, SahenkZ, MalikV, et al.A Phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther, 2015; 23:192–201.
24.
MendellJR, Rodino-KlapacLR, SahenkZ, et al.Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol, 2013; 74:637–647.
25.
MendellJR, GoemansN, LowesLP, et al.Longitudinal effect of eteplirsen vs historical control on ambulation in DMD. Ann Neurol, 2016; 79:257–271.
26.
MonaniUR, SendtnerM, CoovertDD, et al.The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn2/2 mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet, 2000; 9:333–339.
27.
LeTT, PhamLT, ButchbachMER, et al.SMND7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet, 2005; 14:845–857.
28.
FoustKD, WangX, McGovernVL, et al.Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol, 2010; 28:271–274.
29.
LostalW, KodippiliK, YueY, et al.Full-length dystrophin reconstitution with adeno-associated viral vectors. Hum Gene Ther, 2014; 25:552–562.
30.
HarperSQ, HauserMA, DelloRussoC, et al.Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med, 2002; 8:253–261.
